• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在急诊室因心房颤动伴新发短暂性脑缺血发作或小卒中而接受抗凝治疗的患者中,90 天内卒中或短暂性脑缺血发作复发的情况。

Ninety-Day Stroke or Transient Ischemic Attack Recurrence in Patients Prescribed Anticoagulation in the Emergency Department With Atrial Fibrillation and a New Transient Ischemic Attack or Minor Stroke.

机构信息

Department of Emergency Medicine University of Ottawa Ottawa Ontario Canada.

Division of Neurology McMaster University Hamilton Ontario Canada.

出版信息

J Am Heart Assoc. 2023 Apr 18;12(8):e026681. doi: 10.1161/JAHA.122.026681. Epub 2023 Apr 7.

DOI:10.1161/JAHA.122.026681
PMID:37026540
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10227260/
Abstract

Background For patients with atrial fibrillation seen in the emergency department (ED) following a transient ischemic attack (TIA) or minor stroke, the impact of initiating oral anticoagulation immediately rather than deferring the decision to outpatient follow-up is unknown. Methods and Results We conducted a planned secondary data analysis of a prospective cohort of 11 507 adults in 13 Canadian EDs between 2006 and 2018. Patients were eligible if they were aged 18 years or older, with a final diagnosis of TIA or minor stroke with previously documented or newly diagnosed atrial fibrillation. The primary outcome was subsequent stroke, recurrent TIA, or all-cause mortality within 90 days of the index TIA diagnosis. Secondary outcomes included stroke, recurrent TIA, or death and rates of major bleeding. Of 11 507 subjects with TIA/minor stroke, atrial fibrillation was identified in 11.2% (1286, mean age, 77.3 [SD 11.1] years, 52.4% male). Over half (699; 54.4%) were already taking anticoagulation, 89 (6.9%) were newly prescribed anticoagulation in the ED. By 90 days, 4.0% of the atrial fibrillation cohort had experienced a subsequent stroke, 6.5% subsequent TIA, and 2.6% died. Results of a multivariable logistic regression indicate no association between prescribed anticoagulation in the ED and these 90-day outcomes (composite odds ratio, 1.37 [95% CI, 0.74-2.52]). Major bleeding was found in 5 patients, none of whom were in the ED-initiated anticoagulation group. Conclusions Initiating oral anticoagulation in the ED following new TIA was not associated with lower recurrence rates of neurovascular events or all-cause mortality in patients with atrial fibrillation.

摘要

背景

对于在急诊科(ED)就诊的因短暂性脑缺血发作(TIA)或小卒中而发生心房颤动的患者,立即开始口服抗凝治疗而不是推迟门诊随访的决策对其影响尚不清楚。

方法和结果

我们对 2006 年至 2018 年期间在加拿大 13 个急诊科的 11507 名成年人进行了一项前瞻性队列的计划二次数据分析。如果患者年龄在 18 岁或以上,有 TIA 或小卒中的最终诊断,且有先前记录或新诊断的心房颤动,则符合入选条件。主要结局是 TIA 诊断后 90 天内的后续卒中、复发性 TIA 或全因死亡率。次要结局包括卒中、复发性 TIA 或死亡以及大出血发生率。在 11507 例 TIA/小卒中患者中,有 11.2%(1286 例,平均年龄 77.3[11.1]岁,52.4%为男性)发现心房颤动。超过一半(699 例;54.4%)正在服用抗凝药物,89 例(6.9%)在急诊科新开抗凝药物。在 90 天内,心房颤动组有 4.0%的患者发生了后续卒中,6.5%的患者发生了后续 TIA,2.6%的患者死亡。多变量逻辑回归的结果表明,ED 中开具的抗凝药物与这些 90 天结局之间没有关联(复合优势比,1.37[95%CI,0.74-2.52])。发现 5 例大出血,均未发生在 ED 开始抗凝治疗组。

结论

在新发 TIA 后,在 ED 开始口服抗凝治疗与心房颤动患者神经血管事件或全因死亡率的降低无关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6f5/10227260/cef27170a6ed/JAH3-12-e026681-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6f5/10227260/bdb3227e03f4/JAH3-12-e026681-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6f5/10227260/cef27170a6ed/JAH3-12-e026681-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6f5/10227260/bdb3227e03f4/JAH3-12-e026681-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6f5/10227260/cef27170a6ed/JAH3-12-e026681-g002.jpg

相似文献

1
Ninety-Day Stroke or Transient Ischemic Attack Recurrence in Patients Prescribed Anticoagulation in the Emergency Department With Atrial Fibrillation and a New Transient Ischemic Attack or Minor Stroke.在急诊室因心房颤动伴新发短暂性脑缺血发作或小卒中而接受抗凝治疗的患者中,90 天内卒中或短暂性脑缺血发作复发的情况。
J Am Heart Assoc. 2023 Apr 18;12(8):e026681. doi: 10.1161/JAHA.122.026681. Epub 2023 Apr 7.
2
Anticoagulation for newly diagnosed atrial fibrillation and 90-day rates of stroke and bleeding.新诊断心房颤动的抗凝治疗与 90 天内卒中与出血发生率。
CJEM. 2021 May;23(3):325-329. doi: 10.1007/s43678-020-00054-y. Epub 2021 Jan 20.
3
Anticoagulation in Patients With Device-Detected Atrial Fibrillation With and Without a Prior Stroke or Transient Ischemic Attack: The NOAH-AFNET 6 Trial.伴有或不伴有既往卒中和短暂性脑缺血发作的器械检出心房颤动患者的抗凝治疗:NOAH-AFNET 6 试验。
J Am Heart Assoc. 2024 Sep 3;13(17):e036429. doi: 10.1161/JAHA.124.036429. Epub 2024 Aug 27.
4
Impact of Previous Stroke on Clinical Outcome in Elderly Patients With Nonvalvular Atrial Fibrillation: ANAFIE Registry.既往卒中对老年非瓣膜性心房颤动患者临床转归的影响:ANA-FIE 登记研究。
Stroke. 2022 Aug;53(8):2549-2558. doi: 10.1161/STROKEAHA.121.038285. Epub 2022 Apr 20.
5
Real-World Outcomes of Rivaroxaban Treatment in Patients with Both Nonvalvular Atrial Fibrillation and a History of Ischemic Stroke/Transient Ischemic Attack.利伐沙班治疗非瓣膜性心房颤动合并缺血性卒中和短暂性脑缺血发作史患者的真实世界结局。
Cerebrovasc Dis. 2019;48(1-2):53-60. doi: 10.1159/000502883. Epub 2019 Oct 2.
6
Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack.缺血性中风或短暂性脑缺血发作住院的房颤患者使用新型口服抗凝药的情况。
Circ Cardiovasc Qual Outcomes. 2015 Jul;8(4):383-92. doi: 10.1161/CIRCOUTCOMES.114.000907. Epub 2015 Jun 9.
7
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.非瓣膜性心房颤动且既往有卒中和短暂性脑缺血发作患者中应用阿哌沙班、达比加群和利伐沙班与华法林的有效性和安全性。
Stroke. 2017 Aug;48(8):2142-2149. doi: 10.1161/STROKEAHA.117.017474. Epub 2017 Jun 27.
8
Atrial Fibrillation Diagnosis Timing, Ambulatory ECG Monitoring Utilization, and Risk of Recurrent Stroke.心房颤动诊断时机、动态心电图监测的应用与复发性卒中风险
Circ Cardiovasc Qual Outcomes. 2017 Jan;10(1). doi: 10.1161/CIRCOUTCOMES.116.002864.
9
Practice Patterns and Outcomes Associated With Anticoagulation Use Following Sepsis Hospitalizations With New-Onset Atrial Fibrillation.与新发心房颤动的败血症住院患者抗凝治疗的使用相关的实践模式和结局。
Circ Cardiovasc Qual Outcomes. 2023 Mar;16(3):e009494. doi: 10.1161/CIRCOUTCOMES.122.009494. Epub 2023 Feb 28.
10
Comparison of primary and secondary stroke prevention in patients with nonvalvular atrial fibrillation: Results from the RAFFINE registry.非瓣膜性心房颤动患者一级和二级卒中预防的比较:来自 RAFFINE 登记研究的结果。
J Stroke Cerebrovasc Dis. 2022 Dec;31(12):106871. doi: 10.1016/j.jstrokecerebrovasdis.2022.106871. Epub 2022 Nov 7.

本文引用的文献

1
Prospective validation of Canadian TIA Score and comparison with ABCD2 and ABCD2i for subsequent stroke risk after transient ischaemic attack: multicentre prospective cohort study.前瞻性验证加拿大 TIA 评分,并与 ABCD2 和 ABCD2i 进行比较,以评估短暂性脑缺血发作后后续卒中风险:多中心前瞻性队列研究。
BMJ. 2021 Feb 4;372:n49. doi: 10.1136/bmj.n49.
2
The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation.2020 年加拿大心血管学会/加拿大心律学会心房颤动管理综合指南。
Can J Cardiol. 2020 Dec;36(12):1847-1948. doi: 10.1016/j.cjca.2020.09.001. Epub 2020 Oct 22.
3
Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline.
卒中或短暂性脑缺血发作合并非瓣膜性心房颤动患者预防卒中及其他血栓栓塞事件的二级预防抗栓治疗:欧洲卒中组织指南
Eur Stroke J. 2019 Sep;4(3):198-223. doi: 10.1177/2396987319841187. Epub 2019 Apr 9.
4
Canadian stroke best practice recommendations: Secondary prevention of stroke, sixth edition practice guidelines, update 2017.加拿大中风最佳实践推荐:中风二级预防,第六版实践指南,2017 年更新。
Int J Stroke. 2018 Jun;13(4):420-443. doi: 10.1177/1747493017743062. Epub 2017 Nov 24.
5
Resident Physicians Choices of Anticoagulation for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation.非瓣膜性心房颤动患者卒中预防的住院医师抗凝选择。
Can J Cardiol. 2016 Jun;32(6):824-8. doi: 10.1016/j.cjca.2015.08.004. Epub 2015 Aug 14.
6
Rates and Determinants of 5-Year Outcomes After Atrial Fibrillation-Related Stroke: A Population Study.心房颤动相关性卒中后5年结局的发生率及决定因素:一项人群研究。
Stroke. 2015 Dec;46(12):3488-93. doi: 10.1161/STROKEAHA.115.011139. Epub 2015 Oct 15.
7
National survey of emergency physicians for transient ischemic attack (TIA) risk stratification consensus and appropriate treatment for a given level of risk.针对短暂性脑缺血发作(TIA)风险分层共识以及给定风险水平下的适当治疗,对急诊医师进行的全国性调查。
CJEM. 2016 Jan;18(1):10-8. doi: 10.1017/cem.2015.57. Epub 2015 Jul 31.
8
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.新型口服抗凝剂与华法林治疗心房颤动患者的疗效和安全性比较:随机试验的荟萃分析。
Lancet. 2014 Mar 15;383(9921):955-62. doi: 10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.
9
Edoxaban versus warfarin in patients with atrial fibrillation.依度沙班与华法林用于房颤患者。
N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19.
10
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.在心房颤动患者中,Xa因子抑制剂与维生素K拮抗剂预防脑栓塞或全身性栓塞的比较
Cochrane Database Syst Rev. 2013 Aug 8(8):CD008980. doi: 10.1002/14651858.CD008980.pub2.